Anti-CGRP Monoclonal Antibodies: A New Option for Migraine Treatment
Calcitonin Gene-Related Peptide (CGRP) blocking medication is the news treatment available to prevent and treat chronic migraines. Chronic migraines are classified as intense headaches, alongside other migraine symptoms, lasting for 15 or more days per month.
What is Calcitonin Gene-Related Peptide (CGRP)?
CGRP is an amino acid peptide produced in the brain to attach to neurons in the brain.. These peptides are greater in the bloodstream of individuals experiencing chronic migraines. CGRP is believed to be the root cause of chronic and episodic migraines. CGRP not only causes migraines, but also causes the pain associated with them to intensify. CGRP migraine treatment assists in preventing migraines, shortening the length of migraine episodes, and lessening the pain and symptoms associated with migraines.
How do Anti-CGRP Monoclonal Antibodies Work?
The Anti-CGRP Monoclonal Antibodies work by by blocking the neurons to which where CGRP attaches. Monoclonal Antibodies adhere to the CGRP receptor on the neuron and prevents the CRGP from attaching to the nerve.
What Medications areAnti-CGRP Monoclonal Antibodies?
There are 3 versions of this type of medication available: erenumab, fremanezumab and galcanezumab. These medications are taken via injection or automatic pen. Dosage depends on the severity and frequency of migraines and is based on an individual basis.
Who is a Candidate for Anti-CGRP Monoclonal Antibodies?
Anti-CGRP Monoclonal Antibodies treatment may be considered for individuals who have chronic migraines and who also have tried two or three preventative medications or onabotulinumtoxinA and had either a lack of response, intolerable side-effects or no response to these treatment options. These Monoclonal Antibodies treatments are more convenient as they are normally only taken once or twice per month and are considered a preventative type of medication. A physician should be consulted to determine who will benefit from this type of treatment. Any side-effects experienced while taking CGRP treatment should be conveyed to the physician
Risks of Treatment
Due to the recent release of CGRP migraine treatment, long-term risks are not fully explored at this time. Infection or pain is possible at the injection site. New needles, properly cleaned injection site, and clean hands are essential when using these injections. Anti-CGRP Monoclonal Antibodies medications can possibly constrict blood vessels resulting in hypertension. CGRP helps heal wounds and keeps digestive organs healthy. It is unsure at this time if the blocking of this peptide could affect the digestive system or cause issues with wound healing. Advanced medical research are in the process of being conducted on these drugs.